antiandrogens/vėmimas

Nuoroda įrašoma į mainų sritį

StraipsniaiKlinikiniai tyrimaiPatentai

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 26 rezultatus

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Although antiandrogen withdrawal has moderate efficacy in patients with hormone refractory prostate carcinoma (HRPC), the effect of the simultaneous suppression of adrenal androgens with ketoconazole at the time of antiandrogen withdrawal is not known. METHODS Twenty consecutive patients

[Phase I study of flutamide, a nonsteroidal antiandrogen, in patients with prostatic cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A phase I study of orally administered flutamide (a pure anti-androgen) was performed in 26 patients with prostatic cancer. No side effects were observed in 11 patients receiving single doses of either 125, 250, 375 or 500 mg. However, in the daily dosing schedule of 375, 750, 1125 and 1,500 mg/day

[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The phase II study of flutamide, a pure anti-androgen, was performed to estimate the clinical doses on 165 hormone untreated or treated patients with prostatic cancer. The hormone-untreated patients were given orally flutamide of 90, 375, 750 or 1,125 mg/day in three divided doses daily for 12

Flutamide: an antiandrogen for advanced prostate cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Flutamide is a nonsteroidal pure antiandrogen that acts by inhibiting the uptake and/or binding of dihydrotestosterone to the target cell receptor, thus interfering with androgen action. Flutamide is well absorbed orally and extensively metabolized; its active metabolite, 2-hydroxyflutamide, is

[Uncommon initial symptoms of metastasized carcinoma of the prostate].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Four patients, men aged 81, 65, 69 and 52 years, presented with painless lymphomas, pain in the lower back and legs, venous thrombosis in an arm, and headache, vomiting and other neurological complaints, respectively. They were found to have carcinoma of the prostate with metastases. After

A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Treatment of hormone-refractory prostate carcinoma with chemotherapy is purely palliative, and reported response rates have been low. At the time this study was conducted, there was an urgent need for a trial using potentially efficacious drugs, with quality of life (QL), and serial

Metabolic treatment of cancer: intermediate results of a prospective case series.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND The combination of hydroxycitrate and lipoic acid has been demonstrated by several laboratories to be effective in reducing murine cancer growth. METHODS All patients had failed standard chemotherapy and were offered only palliative care by their referring oncologist. Karnofsky status was

Doxetaxel: new indication. Prostate cancer: a few more weeks.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

(1) The standard treatment for metastatic prostate cancer is hormone therapy, based on medical castration (with an LH-RH agonist) or surgical castration (pulpectomy), possibly combined with an androgen antagonist. For patients with hormone-resistant disease the only cytotoxic agents approved in

[Abnormal behavior and adaptation problems in dogs and cats and their pharmacologic control].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Small animal practitioners are increasingly confronted with patients showing adaptation related problems (ARP) which are expressed as disturbed or abnormal behavior (DAB). As a result, practitioners are asked increasingly to euthanize animals which seemingly cannot be socialized. In healthy dogs and

Hormonal treatment for prostate cancer in Italy. Preliminary data from a survey of the QUABIOS Group.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE An observational study was planned by the QUABIOS group, to survey the hormonal modalities administered to prostate cancer patients in Italy within a time window of 12 months. We report here a summary of treatment schedules and related adverse effects, as recorded at the first

[Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE Effective treatment for hormone refractory prostate cancer was required. This study was to evaluate efficacy of combined chemotherapy of gemcitabine and cisplatin on hormone refractory prostate cancer, and its toxicities. METHODS Fifteen patients with advanced hormone refractory prostate

Flutamide in the treatment of metastatic carcinoma of the prostate.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Twenty-five patients with metastatic carcinoma of the prostate were treated with Flutamide, a non-steroidal anti-androgen. All patients showed progression; the longest response was 120 weeks. The side effects were nausea, vomiting, breast tenderness and gynaecomastia.

[Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The efficacy of an association of cyclophosphamide (CPM) and 5-fluorouracil was studied in 15 patients with prostate cancer not responding to oestrogen therapy, and more particularly its effect on pain due to bone metastases. No objective improvement was noted with this association, but there was a

A phase II study of temozolomide in hormone-refractory prostate cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Hormone-refractory disseminated prostate cancer is a major oncological problem. Preclinical studies with temozolomide, an oral alkylating agent, in prostate cancer have shown encouraging results. In phase I studies the safety of temozolomide in non-prostate cancer patients has been

Comparison of ketoconazole and estramustine for treating patients with castration-resistant prostate cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE We investigated the efficacy of ketoconazole and estramustine before chemotherapy for treating patients with progressive castration-resistant prostate cancer (CRPC) after anti-androgen withdrawal syndrome. METHODS Eighty-four patients who were diagnosed with CRPC and were treated between

Ankstesnis
1
2
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais